Jacob Gary S

Jacob Gary S serves as a Director at Hepion Pharmaceuticals, Inc., a company focused on developing innovative therapies for chronic liver diseases. His recent public disclosure activity includes a significant transaction on February 21, 2024, involving a grant/exercise valued at $217.6K. This disclosure reflects his engagement in the healthcare sector, specifically related to Hepion Pharmaceuticals (HEPA), showcasing his role in the company's strategic initiatives.